

平成 29 (2017) 年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	山下真未、 <u>田中純子</u>	肝疾患総論 疫学	佐々木裕	ここまできた肝臓病診療	中山書店 東京		2017	50-54	○
2)	<u>相崎英樹</u> 、Zheng Xin、 <u>脇田隆字</u>	特集ウイルス肝炎のすべて	小池和彦	医学のあゆみ	医歯薬出版社	東京	2017	1215-1220	○
3)	<u>相崎英樹</u> 、Zheng Xin、石井孝司、 <u>脇田隆字</u> 、砂川富正、大石和徳、 <u>吉岡健太郎</u>	特集進化する B 型肝炎治療「B 型肝炎疫学の最新状況」		消化器・肝臓内科	科学評論社	東京	2017	390-397	○
4)	<u>相崎英樹</u> 、和気健二郎、 <u>脇田隆字</u>	ここまでわかった C 型肝炎ウイルスの感染・複製機構、目覚しく治療効果を発揮する C 型肝炎治療		Mebio	メジカルビュー社	東京	2017	4-13	
5)	永田務、 <u>鶴田修</u> 、河野弘志、森田拓、徳安秀紀、進藤洋一郎、火野坂淳、長田修一郎、前山泰彦、向笠道太、秋葉純、 <u>光山慶一</u> 、 <u>鳥村拓司</u>	鋸歯状病変を併存した大腸癌の臨床病理学的特徴（第 83 回大腸癌研究会優秀発表賞）	杉原健一、五十嵐正広、他編	大腸疾患 NOW 2017-2018	日本メディカルセンター	東京	2017.1	138-148	
6)	川口巧、 <u>鳥村拓司</u>	II. 栄養評価 E.窒素代謝および窒素平衡	一般社団法人日本静脈経腸栄養学会 編	一般社団法人日本静脈経腸栄養学会 静脈経腸栄養テキストブック	南江堂	東京	2017.2	163-167	
7)	Tsutsumi V, Nakamura T, Ueno T, <u>Torimura T</u> , J. Aguirre-Garcia	Structure and Ultrastructure of the Normal and Diseased Liver	Pablo Muriel	Liver Pathophysiology: Therapies and Antioxidants	Academic Press	Boston	2017.3	23-44	

平成 29 (2017) 年度 研究成果の刊行に関する一覧表 【雑誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1) Mukaida K, Hattori N, Iwamoto H, Onari Y, Nishimura Y, Kondoh K, Akita T, <a href="#">Tanaka J</a> , Kohno N	Mustard gas exposure and mortality among retired workers at a poisonous gas factory in Japan: A 57-year follow-up cohort study.	Occupational and Environmental Medicine	74(5)	321-327	2017	
2) Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, <a href="#">Tanaka J</a>	Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in CHB patients: an analysis using time-dependent ROC	Journal of Gastroenterology and Hepatology	32(2)	451-458	2017	○
3) Tada T, Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <a href="#">Tanaka J</a>	Post-treatment levels of $\alpha$ -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C	Hepatology Research	47(10)	1021-1031	2017	○
4) Blach S, Zeuzem S, Manns M, et al. ( <a href="#">Tanaka J</a> 222 人中 202 番目)	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study	The LANCET Gastroenterology & Hepatology	2(3)	161-176	2017	○
5) Sugiyama A, Ohisa M, Nagashima S, Yamamoto C, Chuon C, Fujii T, Akita T, Katayama K, Kudo Y, <a href="#">Tanaka J</a>	Reduced prevalence of hepatitis B surface antigen positivity among pregnant women born after the national implementation of immunoprophylaxis for babies born to hepatitis B virus-carrier mothers in Japan	Hepatology Research	47(12)	1329-1334	2017	○
6) Tada T, Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <a href="#">Tanaka J</a>	Viral Eradication reduces all-Cause Mortality, Including non-Liver-Related Disease, in Patients With Progressive Hepatitis C Virus-Related Fibrosis.	J Gastroenterol Hepatol.	32(3)	687-694	2017	○
7) Matsuo J, Do SH, Yamamoto C, Nagashima S, Chuon C, Katayama K, Takahashi K, <a href="#">Tanaka J</a>	Clustering infection of hepatitis B virus genotype B4 among residents in Vietnam, and its genomic characters both intra- and extra-family	PLOS ONE	12(7)	e0177248	2017	○
8) Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, <a href="#">Tanaka J</a>	Differences in the impact of prognostic factors for hepatocellular carcinoma over time	Cancer Science	108(12)	2438-2444	2017	○
9) Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Akita T, <a href="#">Tanaka J</a>	Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease	Hepatology Communications	1(i9)	899-910	2017	○
10) <a href="#">Tanaka J</a> , Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, Satake M	Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011	Journal of Viral Hepatitis	25(4)	363-372	2017	○
11) Shoji K, Teishima J, Hayashi T, Shinmei S, Akita T, Sentani K, Takeshima Y, Arihiro K, <a href="#">Tanaka J</a> , Yasui W, Matsubara A	A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients	Oncology Letters	14(1)	299-305	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Kaishima T, Akita T, Ohisa M, Sakamune K, Kurisu A, Sugiyama A, Aikata H, Chayama K, <a href="#">Tanaka J</a>	Cost-effectiveness analyses of anti-HCV treatments using QOL scoring among patients with chronic liver disease in the Hiroshima prefecture	Hepatology Research	in press	in press	2017	○
13)	Fujimoto M, Chuon C, Nagashima S, Yamamoto C, Ko K, Svay S, Hok S, Lim O, Ohisa M, Akita T, Katayama K, Matsuo J, Takahashi K, <a href="#">Tanaka J</a>	A seroepidemiological survey of the effect of hepatitis B vaccine and hepatitis B and C virus infections among elementary school students in Siem Reap province, Cambodia	Hepatology Research	48(3)	E172-E182	2018	○
14)	Sugiyama A, Fujii T, Nagashima S, Ohisa M, Yamamoto C, Chuon C, Akita T, Matsuo J, Katayama K, Takahashi K, <a href="#">Tanaka J</a>	Pilot study for hepatitis virus screening among employees and effective approach to encourage screened positive employees to receive medical care in Japan	Hepatology Research	48(3)	E291-E302	2018	○
15)	Fujii T, Ohisa M, Sako T, Harakawa T, Sakamune K, Nagashima S, Sugiyama A, Matsuura Y, <a href="#">Tanaka J</a>	Incidence and risk factors of colorectal cancer based on 56,324 health checkups: 7 years retrospective cohort study	Journal of Gastroenterology and Hepatology	33(4)	855-862	2018	
16)	Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, <a href="#">Tanaka J</a>	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers	Journal of Gastroenterology and Hepatology	33(4)	918-925	2018	○
17)	Iwasaki S, Shigeishi H, Akita T, <a href="#">Tanaka J</a> , Sugiyama M	Efficacy of cognitive-behavioral therapy for patients with temporomandibular disorder pain-systematic review of previous reports	International Journal of Clinical and Experimental Medicine	11(2)	500-509	2018	
18)	Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, <a href="#">Tanaka J</a>	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy	Alimentary Pharmacology & Therapeutics	47(7)	1012-1022	2018	○
19)	Razavi-Shearer D, Gamkrelidze I, Nguyen M H, et al. ( <a href="#">Tanaka J</a> . 196人中 175 番目)	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study	The LANCET Gastroenterology & Hepatology	in press	in press	2018	○
20)	<a href="#">田中純子</a>	わが国の HCV 感染症の現状と展望	Mebio	34(1)	14-22	2017	○
21)	<a href="#">田中純子</a> 、 <a href="#">片山恵子</a>	C 型肝炎の疫学—最近の動向	消化器・肝臓内科	1(1)	59-65	2017	○
22)	<a href="#">田中純子</a>	C 型肝炎の疫学	医学と薬学	74(5)	517-523	2017	○
23)	<a href="#">海嶋照美</a> 、 <a href="#">片山恵子</a> 、 <a href="#">田中純子</a>	ウイルス性肝炎の最新疫学	保健師ジャーナル	73(6)	475-480	2017	○
24)	<a href="#">田中純子</a>	わが国における B 型肝炎・C 型肝炎ウイルスキャリアの現状	医学のあゆみ	262(14)	1221-1232	2017	○
25)	<a href="#">杉山文</a> 、 <a href="#">海嶋照美</a> 、 <a href="#">坂宗和明</a> 、 <a href="#">田中純子</a>	肝炎医療コーディネーターの活動実態調査研究—広島県および全国調査の結果から—	肝臓	59(1)	33-40	2018	○
26)	<a href="#">杉山文</a> 、 <a href="#">秋田智之</a> 、 <a href="#">片山恵子</a> 、 <a href="#">田中純子</a>	わが国の HBV 感染症の現状と展望	Mebio	35(1)	14-23	2018	○
27)	<a href="#">秋田智之</a> 、 <a href="#">田中純子</a>	肝癌の疫学	日本臨牀	76(2)	175-182	2018	○
28)	<a href="#">田中純子</a>	わが国における肝炎ウイルス感染者の動向	消化器・肝臓内科	3(3)	270-276	2018	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
29)	Michiyo Tomioka, Kathryn Braun, Mieko Homma, <u>Hiroaki Nobuhara</u> , Tomio Kubota, Hiromichi Sakai	Perceptions of Factors Impacting Longevity among Hawai'i Older Adults	HAWAII JOURNAL OF MEDICINE & PUBLIC HEALTH	76(3)	71-76	2017	
30)	中島富志子, 萱場一則, <u>延原弘章</u>	社会経済的要因と特定健診結果の関連についてー市町村単位の生態学的研究ー	厚生指標	64 (12)	14-22	2017	
31)	Yasuyo Sato, Sachiko Okamoto, Kazunori Kayaba, <u>Hiroaki Nobuhara</u> , Keiko Soeda	Effectiveness of role-play in hazard prediction training for nursing students: A randomized controlled trial	Journal of Nursing Education and Practice	8(2)	1-7	2018	
32)	Iwamoto M, Cai D, Sugiyama M, Suzuki R, <u>Aizaki H</u> , Ryo A, Ohtani N, Tanaka Y, Mizokami M, Wakita T, Guo H, Watashi K	Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication.	Sci Rep.	6	10620	2017	
33)	Tsutsumi T, Okushin K, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, <u>Aizaki H</u> , Suzuki T, Matsuura Y, Koike K	Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver.	PLOS ONE	20	e0170461	2017	
34)	Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, <u>Aizaki H</u> , Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T	A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.	Hepatology	65	1104-1116	2017	
35)	Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, <u>Torimura T</u> ; Kurume Liver Cancer Study Group of Japan	Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.	Mol Clin Oncol.	7	1013-1020	2017	
36)	Abe M, Yoshida T, Akiba J, Ikezono Y, Wada F, Masuda A, Sakaue T, Tanaka T, Iwamoto H, Nakamura T, Sata M, Koga H, Yoshimura A, <u>Torimura T</u>	STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury.	World J Gastroenterol.	23	6833-6844	2017	
37)	Tamada T, Korenaga M, Yamamoto A, Higaki A, Kanki A, Nishina S, <u>Hino K</u> , Ito K	Assessment of clinical and magnetic resonance imaging features of de novo hypervascular hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging.	Hepato Res	47	E152-160	2017	○
38)	Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, <u>Hino K</u> , Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.	J Gastroenterol	Epub ahead of print	Epub ahead of print	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
39)	Koyama N, Hata J, Sato T, Tomiyama Y, <u>Hino K</u>	Assessment of hepatic fibrosis with superb microvascular imaging in hepatitis C virus-associated chronic liver diseases.	Hepatol Res	47	593-597	2017	○
40)	Masugi Y, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, <u>Hino K</u> , Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M	Quantitative Assessment of Liver Fibrosis Reveals a Nonlinear Association With Fibrosis Stage in Nonalcoholic Fatty Liver Disease	Hepatology Communications	-	-	2017 (in press)	
41)	Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, <u>Hino K</u>	Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease	Hepatol Res	-	-	2017 (in press)	○
42)	Yamane D, Selitsky SR, <u>Shimakami T</u> , Li Y, Zhou M, Honda M, Sethupathy P, Lemon SM	Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3' variants	Nucleic Acids Res	45	4743-4755	2017	
43)	Wang X, Oishi N, <u>Shimakami T</u> , Yamashita T, Honda M, Murakami S, Kaneko S	Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.	World J Gastroenterol.	23	3252-3261	2017	
44)	Suda T, <u>Shimakami T</u> , Shirasaki T, Yamashita T, Mizukoshi E, Honda M, Kaneko S	Reactivation of hepatitis B virus from an isolated anti-HBc positive patient after eradication of hepatitis C virus with direct-acting antiviral agents.	J Hepatol.	67	1108-1111	2017	○
45)	Ishida K, <u>Shimakami T</u> , Kaneko S	The use of direct-acting antivirals in the treatment of elderly patients with hepatitis C Virus infection.	Nihon Ronen Igakkai Zasshi.	54	375-380	2017	○
46)	Funaki M, Kitabayashi J, <u>Shimakami T</u> , Nagata N, Sakai Y, Takegoshi K, Okada H, Murai K, Shirasaki T, Oyama T, Yamashita T, Ota T, Takuwa Y, Honda M, Kaneko S	Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo.	Sci Rep.	7	16978	2017	
47)	Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C1, Mikami S, Asano T, Chuganji Y, <u>Matsuzaki Y</u> , Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C	Hepatol Res.	47 (13)	1429-1437	2017	
48)	Miyazaki T, Nakamura Y, Ebina K, Mizushima T, Ra SG, Ishikura K, <u>Matsuzaki Y</u> , Ohmori H, Honda A	Increased N-acetyltaurine in the skeletal muscle after endurance exercise in rat	Adv Exp Med Biol	975	403-411	2017	
49)	Higashimura Y, Baba Y, Inoue R, Takagi T, Mizushima K, Ohnogi H, Honda A, <u>Matsuzaki Y</u> , Naito Y	Agaro-oligosaccharides regulate gut microbiota and adipose tissue accumulation in mice	J Nutr Sci Vitaminol (Tokyo)	63(4)	269-276	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
50)	Hirayama T, Ikegami T, Honda A, Miyazaki T, Yara S, Kohijima M, Nakamuta M, <u>Matsuzaki Y</u>	Difference of serum 4 $\beta$ -hydroxycholesterol levels of patients with chronic HCV infection: A possible impact on the efficacy and safety of IFN-free treatment	Internal Medicine	Epub ahead of print		2017	
51)	Ra SG, Miyazaki T, Kojima R, Komine S, Ishikura K, Kawanaka K, Honda A, <u>Matsuzaki Y</u> , Ohmori H	Effect of BCAA supplement timing on exercise-induced muscle soreness and damage: a pilot placebo-controlled double-blind study	J Sports Med Phys Fitness	Epub ahead of print		2017	
52)	Iwamoto J, Murakami M, Konishi N, Monma T, Ueda H, Yara S, Hirayama T, Ikegami T, Honda A, <u>Matsuzaki Y</u>	Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNF $\alpha$ Antibody in a Patient with Intestinal Bechet Disease	Internal Medicine	Epub ahead of print		2017	
53)	Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, <u>Matsuzaki Y</u> , Iwakiri K	Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema	J Gastroenterol Hepatol	Epub ahead of print		2017	
54)	Asahina Y, toh Y, Ueno Y, <u>Matsuzaki Y</u> , Takikawa Y, Yatsuhashi H, Genda T, Ikeda F, Matsuda T, Dvory-Sobol H, Jiang D, Massetto B, Osinusi AO, Brainard DM, McHutchison JG, Kawada N, Enomoto N	Ledipasvir-Sofosbuvir for Treating Japanese Patients With Chronic Hepatitis C Virus Genotype 2 Infection	Liver Int.	Epub ahead of print		2018	
55)	Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, <u>Matsuzaki Y</u> , Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease	Hepatol Res	Epub ahead of print		2018	
56)	Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, Monma T, Konishi N, Yara S, Miyazaki T, Saitoh Y, Ikegami T, <u>Matsuzaki Y</u>	Detection of gut dysbiosis due to reduced clostridium subcluster IXVa using the fecal or serum bile acid profile	Inflamm Bowel Dis.	In press		2018	
57)	宮崎照雄, 池上正, 本多彰, <u>松崎靖司</u>	連載【各都道府県における肝臓疾患対策取り組みの現状】茨城県における肝疾患対策取り組みの現状.	肝臓クリニカルアップデート	3(1)	81-85	2017	○
58)	Tada T, <u>Kumada T</u> , Toyoda H, Tsuji K, Hiraoka A, Tanaka J	Impact of FIB-4index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.	J Gastroenterol Hepatol.	32	451-458	2017	○
59)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J	Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.	J Gastroenterol Hepatol.	32	687-694	2017	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
60)	Toyoda H, Tada T, Tachi Y, Hirai T, Yasuda S, Honda T, Hayashi K, Ishigami M, Goto H, <u>Kumada T</u>	Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.	Antivir Ther	22	185-193	2017	
61)	Toyoda H, <u>Kumada T</u> , Tada T	Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.	Hepatology	64	1818-1819	2017	
62)	Rho JH, Ladd JJ, Li CI, Potter JD, Zhang Y, Shelley D, Shibata D, Coppola D, Yamada H, Toyoda H, Tada T, <u>Kumada T</u> , Brenner DE, Hanash SM, Lampe PD	Protein and glycomic plasma markers for early detection of adenoma and colon cancer.	Gut			2017	
63)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J	Post-treatment levels of $\alpha$ -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.	Hepatol Res.	47	1021-1031	2017	○
64)	Toyoda H, <u>Kumada T</u> , Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B	J Hepatol.	66	521-527	2017	○
65)	Toyoda H, Tada T, Takaguchi K, Senoh T, Shimada N, Hiraoka A, Michitaka K, Ishikawa T, <u>Kumada T</u>	Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.	J Viral Hepat.	24	472-476	2017	
66)	Tada T, <u>Kumada T</u> , Toyoda H, Mizuno K, Sone Y, Akita T, Tanaka J	Progression of Liver Fibrosis Is Associated With Non-Liver-Related Mortality in Patients With Nonalcoholic Fatty Liver Disease	HEPATOLOGY COMMUNICATIONS	1	899-910	2017	
67)	Honda T, Ishigami M, Ishizu Y, Kuzuya T, Hayashi K, Ishikawa T, Murakami Y, Iwadate M, Umeyama H, Toyoda H, <u>Kumada T</u> , Katano Y, Goto H, Hirooka Y	Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B.	Clin Microbiol Infect.	23	407.e1-407.e7	2017	
68)	Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, <u>Kumada T</u>	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.	Br J Cancer	116	441-447	2017	
69)	Inoue T, Hmwe SS, Shimada N, Kato K, Ide T, Torimura T, <u>Kumada T</u> , Toyoda H, Tsubota A, Takaguchi K, Wakita T, Tanaka Y	Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.	PLOS ONE	12	e0170667	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
70)	Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, MoF, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, SangroB, Lai P, <u>Kumada T</u> , Johnson PJ	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.	Br J Cancer	116	448-454	2017	
71)	Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, <u>Kumada T</u> , Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwara E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y	Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.	Gastroenterology	152	1383-1394	2017	
72)	Toyoda H, <u>Kumada T</u> , Tada T, Mizuno K, Kobayashi N, Inukai Y, Takeda A, Sone Y	Discrepant imaging findings of portal vein thrombosis with dynamic computed tomography and computed tomography during arterial portography in hepatocellular carcinoma: possible cause leading to inappropriate treatment selection.	Clin J Gastroenterol	10	163-167	2017	
73)	Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, <u>Kumada T</u> , Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan	Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey.	J Gastroenterol	21		2017	
74)	Tada T, <u>Kumada T</u> , Toyoda H, Mizuno K, Sone Y, Kataoka S, Hashinokuchi S	Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response	J Gastroenterol Hepatol.	32	1982-1988	2017	
75)	Tada T, <u>Kumada T</u> , Toyoda H	Reply to: "HBV markers for HCC prediction: Three heads are better than two?"	J Hepatol	67	204-205	2017	
76)	Tada T, <u>Kumada T</u> , Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, Nouso K, Kariyama K, Ishikawa T, Hirooka M, Hiasa Y	Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan.	Cancer Sci.	108	1414-1420	2017	
77)	Hiraoka A, <u>Kumada T</u> , Michitaka K, Toyoda H, Tada T, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S	Real-Life Practice Experts For Hepatocellular Carcinoma (HCC) (RELPEC) Study Group and The HCC 48 Group (HCC experts from 48 clinics). Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation.	Mol Clin Oncol.	6	455-461	2017	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
78)	Matsushima-Nishiwaki R, Toyoda H, Takamatsu R, Yasuda E, Okuda S, Maeda A, Kaneoka Y, Yoshimi N, <u>Kumada T</u> , Kozawa O	Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway	Biochim Biophys Acta.	1863	1629-1639	2017	
79)	Dengler M, Stauffer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, <u>Kumada T</u> , Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis	Oncotarget	8	46234-46248	2017	
80)	Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, <u>Kumada T</u> , Chayama K, Sakamoto N	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan	J Gastroenterol	53	119-128	2017	
81)	Toyoda H, <u>Kumada T</u> , Tada T	Hepatitis B Core-Related Antigen: A Possible Indicator for the Termination of Prophylactic Nucleos(t)ide Analogue Therapy in Patients After Immunosuppressive Therapy	Am J Gastroenterol	112	969-970	2017	
82)	Hiraoka A, <u>Kumada T</u> , Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouse K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics)	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications	Liver Cancer	6	204-215	2017	
83)	Toyoda H, Hiraoka A, Tada T, Michitaka K, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S, <u>Kumada T</u>	Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis	Ther Apher Dial	21	465-472	2017	
84)	Tada T, <u>Kumada T</u> , Toyoda H, Kobayashi N, Akita T, Tanaka J	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers.	J Gastroenterol Hepatol			2017	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
85)	Toyoda H, <u>Kumada T</u> , Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, Tanaka J	Differences in the impact of prognostic factors for hepatocellular carcinoma over time	Cancer Sci.	108	2438-2444	2017	○
86)	Kobayashi N, <u>Kumada T</u> , Toyoda H, Tada T, Ito T, Kage M, Okanoue T, Kudo M	Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients	Dig Dis	35	602-610	2017	
87)	Toyoda H, <u>Kumada T</u> , Tada T, Mizuno K	Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR	J Hepatol			2017	
88)	Toyoda H, <u>Kumada T</u> , Tada T, Yama T, Mizuno K	Significance of Day-1 Viral Response of Hepatitis C Virus in Patients with Chronic Hepatitis C Receiving Direct-acting Antiviral Therapy	J Gastroenterol Hepatol			2017	
89)	Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, <u>Kumada T</u> , Tanaka Y	High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues	J Gastroenterol			2017	
90)	Tada T, <u>Kumada T</u> , Toyoda H, Saibara T, Ono M, Kage M	New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease	Biomarkers			2018	
91)	Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, <u>Kumada T</u> , Iio E, Tanaka Y, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease	Hepatol Res			2018	